Company
Cronos Group Inc
NASDAQ:CRON
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones®.
114 stories · page 1 of 2
Buds & Duds: Cannabis stocks drop as Cowen cuts Canadian pot sector outlook
The Flowr Corporation and Canntab Therapeutics both saw early gains on Monday after Health Canada approvals
Buds & Duds: Cannabis stocks stay flattish, Youngevity dips after reorganizing its board
The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, lost 0.3% to 96.8 points
Buds & Duds: Cannabis stocks lackluster heading into weekend; HEXO files financial statements
Most major cannabis stocks found themselves in the red on Friday morning
Buds & Duds: Cannabis stocks cruise flat on Thursday, but Codebase Ventures jumps as it explores CBD opportunities in Europe
Also on the move Thursday were Empower Clinics, Cronos and Aphria
Archive
NA Proactive news snapshot: CytoDyn, Namaste Technologies, Osino Resources UPDATED …
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Heritage Cannabis to supply Cronos with vaporizer devices for Canadian adult-use, medical markets
The manufacturing agreement has a two-year term with an option to extend, at an annual potential contract value of C$35 million
Buds & Duds: Cannabis stocks trip and stumble, HEXO sinks on 3Q earnings
Also on the move were MariMed, Cronos, Namaste, Terra Tech and High Hampton
Buds & Duds: Cannabis stocks slip but Valens shares jump on expanded extraction deal with Tilray
Also on the move were Origin House, Cresco, High Hampton, Cronos, Planet 13 and Emerald Health
Buds & Duds: Cannabis stocks start the week with gusto, as Tilray shares soar
Also on the move were Harvest One, Cronos, Cresco and Green Growth Brands
Buds & Duds: Cannabis stocks cruise flat; Cronos shares soar on coveted double upgrade
Also on the move were True Leaf, MedMen, TILT and Tilray
Investments and investor services
Cronos Group shares pop on rare double upgrade Bank of America Merrill Lynch analyst
Christopher Carey upgraded the cannabis company to Buy from Underperform and boosted his price target to $20 from $13
Buds & Duds: Cannabis stocks climb; Canntab shares soar on hemp-cultivation licence
Also on the move were PreveCeutical, The Supreme Cannabis Company, Cronos, Golden Leaf Holdings and Isodiol International
Cronos inks cannabis concentrate supply agreement with MediPharm Labs
The cannabis companies also agreed to a tolling deal in which Cronos will pay MediPharm to process its cannabis into resin
Buds & Duds: Cannabis stocks sink; Newstrike and Hexo shares tumble even as acquisition moves forward
Also on the move were Cronos, Aurora, TILT and Vivo
Buds & Duds: Cannabis stocks close up on Friday after flat start; Next Green Wave shares surge
Also on the move were Valens, Cronos, TerraTech and Aurora
Cronos shares sink as it reports wider loss and revenue miss in 1Q
Cronos shares sank on Thursday after the cannabis producer announced its earnings results showing the producer widened its loss and missed on revenue in 1Q
Buds & Duds: Cannabis stocks tumble led by Cronos 1Q earnings that miss the mark
Also on the move were Canopy Growth, CV Sciences, High Hampton and Aleafia
Buds & Duds: Cannabis stocks trip but Aleafia bucks the trend as it enters German medical cannabis market
Also on the move were True Leaf, GrowGeneration, Planet 13 and Cronos
Buds & Duds: Cannabis stocks start the week with a thud; Cronos and Tilray lag on price cuts
Also on the move were Tilray, Planet 13, True Leaf, Auxly and Aleafia Health
Buds & Duds: Cannabis stocks nudge upwards; CROP Infrastructure shares rise on nursery completion in Nevada
Also on the move were Golden Leaf, Cronos, GrowGeneration, Aleafia Health and OrganiGram
Buds & Duds: Cannabis stocks slip; Empower shares power up
Also on the move were Crop Infrastructure, TILT Holdings, Cronos and Terra Tech
Buds & Duds: Cannabis stocks tumble led by mixed 3Q earnings from Aphria
Also on the move were Valens GroWorks Corp, Chemistree Technology, Cronos Group and Golden Leaf
Buds & Duds: Cannabis stocks sag; CROP Infrastructure shares jump as it broadens California footprint
Also on the move were Next Green Wave, Aurora Cannabis and Cronos Group
Buds & Duds: Cannabis stocks slide steeply as investors pause; 1933 Industries shares pop on Nevada licensing deal
Also on the move were RedFund Capital, Planet 13 Holdings, Isodiol International and OrganiGram
Buds & Duds: Cannabis stocks inch lower as Valens shares soar after releasing Canadian post-legalization report
Also on the move were 1933 Industries Inc, New Age Beverages Corp, and Tilray Inc
Investments and investor services
Cronos stock swoons on a trio of downgrades to the cannabis-focused company
One analyst downgraded the stock to Sell, citing a 'soft start' to Canada's legal cannabis market
Buds & Duds: Cannabis stocks tumble on back of Cronos downgrade
Also on the move was Canopy Growth, CV Sciences, India Globalization Capital and True Leaf Medicine International
Investments and investor services
Canadian markets close flat as global growth concerns persist
Cannabis stocks gave back gains as signs of a global slowdown hindered investor appetite
Buds & Duds: Cronos shares tumble, Newstrike Brands soars on results
Also on the move were Curaleaf Holdings, Newstrike Brands and Isodiol International
Cronos Group reports higher revenue but widening loss in mixed 4Q earnings results
In March, the Canadian cannabis producer closed a $2.4 billion investment from Marlboro cigarette maker Altria Inc
Buds & Duds: The Green Organic Dutchman shares jump as it launches Growers’ Circle; Cronos shares up ahead of earnings
Also on the move were ICC International Cannabis Corp, Canopy Growth Corporation and Eve & Co Inc
Buds & Duds: Terra Tech leads cannabis stocks higher as US markets break losing streak
Cannabis stocks on the rise include Valens, Green Organic Dutchman and Aurora Cannabis
Investments and investor services
Buds & Duds: Cannabis stocks blunted by widespread market woes
Among the stocks to drop Friday were Tilray and Cronos
Buds & Duds: Arcadia Biosciences stock soars after earning Hawaii hemp license
Also making gains was Harvest One, which agreed to acquire biotech company Delivra
Archive
Buds & Duds: Pot stocks sink as CannTrust Holdings stumbles on first trading day on NYSE
Cronos Group also took a hit after Jefferies analyst Owen Bennett kicked off his coverage on the stock with an Underperform rating
Investments and investor services
Vegetable grower Village Farms International takes a seat at the cannabis table (Part 1)
A two-part dive into the Canada-based hydroponic grower's transition from tomatoes, peppers and cucumbers to cannabis
Archive
Buds & Duds: iAnthus Capital rallies after closing its acquisition of MPX Bioceutical
Cronos Group declined following a downgrade to Hold by GMP Securities while Aphria fell after its board rejected Green Growth's hostile takeover bid
Aphria shares pop after short-seller Andrew Left moves to sell stake
Aphria shares are trading higher before the opening bell after short-seller Andrew Left moved to take profits in the cannabis company
Short-seller Andrew Left of Citron Research sounds off: take profits in Aphria, short Cronos Group
Citron Research said 'Canadian weed' has 'run too far' and would be moving into US names
Archive
Buds & Duds: Shares of Weekend Unlimited surge after POT ticker win
Shares of Weekend Unlimited jumped more than 134% on Friday, after it announced it won the lottery for the POT stock ticker
Buds & Duds: High Times for HEXO Corp and Cronos Group
HEXO Corp won approval this week for a listing on the NYSE American Exchange
Archive
Buds & Duds: Canopy Growth still picking up steam thanks to New York hemp license
Cannabis stocks in the US and Canada are struggling in early trade
Buds & Duds: Lexaria Bioscience shares jump on partnership deal; Tilray sinks as stock lock-up period ends
The bulk of US and Canadian cannabis companies lagged on Tuesday, after attorney general nominee William Barr said that the current system around marijuana laws is 'untenable' and he supports prohibiting marijuana across the US
Cannabis companies heartened as New York weighs legalization and US farm bill nears passage
Crop Infrastructure and Redfund Capital are companies encouraged by political developments supporting the medical and recreational marijuana industry
Canopy Growth remains the superior bet when playing cannabis stocks, says Jim Cramer
The benefits Canopy Growth holds over Cronos are scale and a $4 billion investment by Constellation Brands
Buds & Duds: Aphria and Cronos riding high while Canopy Growth and Tilray shares slip
Aphria shares are back on the rise after taking a hit from a short-seller report
Altria makes C$2.4B investment in Canadian cannabis company Cronos Group
The tobacco giant Altria is looking to widen its business beyond tobacco while Cronos is looking for a strategic partner to provide capital
Buds & Duds: Dual-listed cannabis stocks surge in Canada, but sink in the US ahead of farm bill decision
The farm bill may legalize hemp and hemp-derived CBD in the US on the federal level
Buds & Duds: Cannabis stocks drop on the back of broader market weakness
Shares of Cronos perked up again after it was reported that the maker of Marlboro cigarettes is in initial discussions to either take a stake in or possibly acquire the company
Investments and investor services
EARLY MOVERS: Restoration Hardware shares shine as it raises revenue guidance: Toll Brothers slide
Also in the frame before the New York bell are Smartsheet Inc, Toll Brothers, Dollar General Corp, Aphria Inc and Cronos Group Inc
Altria in investment talks with Canadian cannabis company Cronos
The legalization of marijuana by Canada is prompting renewed interest in investment in the country’s cannabis companies
Buds & Duds: Canopy Growth, Tilray, Aurora Cannabis, MedMen and other notable names take a hit
Cannabis-focused life-science company CV Sciences was one of the few gainers on the North American Marijuana Index
Buds & Duds: Cannabis stocks have a mixed Thursday after broader markets slip
Cannabis stocks saw a host of red and green across the board on Thursday
Buds & Duds: cannabis stocks end on a low note, despite news from Congress
Cannabis stocks dropped Tuesday, despite news that Congress was close to finishing a farm bill, which includes provisions to legalize hemp
Buds & Duds: Rough start to the week for cannabis stocks as Canopy Growth and Aurora Cannabis shares dip
GW Pharmaceuticals was a top gainer on the North American Marijuana Index following positive data from its trial of Epidiolex, a treatment for a form of childhood epilepsy
Buds & Duds: Industrial Properties, ICC international Cannabis the only gainers in cannabis space
Innovative Industrial Properties, which leases medical cannabis facilities, was one of the only gainers on the North American Marijuana Index
Tilray revenue soars 85% in 3Q as company takes aim at cannabis expansion
Higher operating expenses, expansion of international teams and costs related to its IPO accounted for an increase in losses
Cronos revenue nearly triples after Canada cannabis legalization, but swings to a loss for third quarter
On its list of quarterly highlights is a new partnership with Ginkgo Bioworks to produce cannabinoids through fermentation
Buds & Duds: Cannabis stocks were fired up after midterms, but end the week on a low note
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals in Tuesday’s election
Shorts to hike positions in cannabis majors Canopy Growth, Aurora Cannabis, Cronos Group and Tilray, says S3 Partners
Short-sellers are betting on a reversal in what they see as an overheated, overvalued cannabis sector
Buds & Duds: Cannabis stocks on a high after midterm wins and Sessions’ exit
Voters in Michigan, Missouri and Utah voted ‘yes’ on marijuana proposals Tuesday
Buds & Duds: Cannabis stocks riding high ahead of the US midterm election
Voters in Michigan, North Dakota, Missouri and Utah will vote on marijuana proposals Tuesday
Cannabis stocks end the week on a mixed note as some major players take a hit
Big names in cannabis, including Aurora Cannabis and Cronos, fared well Friday afternoon
Canadian cannabis company Aphria plans to list on NYSE to boost liquidity, investor interest
The Ontario-based cannabis company filed with the SEC last week but has yet to set a date for its trading debut
Cronos Group partners with foundation for cannabinoid-based skin care treatments
Research will look into potential applications of cannabinoids to regulate skin health and treat skin disorders
Veritas kicks off coverage of Canada's cannabis industry with Sell ratings Canopy Growth, Aphria, Aurora Cannabis and Cronos
'Our analysis suggests that the market still lacks perspective when it comes to the size, shape and sustainability of Canada’s proverbial pot of gold,' argues analyst Stuart Rolfe
Andrew Left’s Citron Research sets $65 price target for Pyxus International stock, says it's 'a perfect hedge'
Pyxus shares soared after the short-seller released a report saying Pyxus would be the greatest beneficiary if tobacco giant Altria takes a stake in cannabis grower Aphria
Andrew Left’s Citron Research is shorting cannabis companies left and right, but not this one
The tobacco company’s Canadian subsidiary recently received a cannabis cultivation license from Health Canada
Tilray and Cronos Group stock fall in holiday-tinged market dealings
Tilray has been rocked by volatile trading and Cronos has signed a string of partnerships in the cannabis space; New Age Beverage and DAVIDsTEA tumbled as well
Short-seller Andrew Left’s Citron Research doubles down on Namaste Technologies, calls it a 'fraud'
Citron Research published a seven-page report that it claims proves the cannabis company is a fraud
Short-seller Andrew Left’s Citron Research sets sights on India Globalization Capital
The infrastructure-meets-pharmaceutical company recently announced a line of CBD-infused energy drinks
Why America's cannabis companies are flocking to Canada to woo public investors
The Canadian Securities Exchange is becoming a wildly popular destination for US cannabis companies rejected by the NYSE and Nasdaq
Andrew Left of Citron Research looking to create cannabis-fund, says Bloomberg
The fund would invest in Canadian-listed cannabis companies
Buds & Duds: Cannabis stocks have a bumpy Tuesday but perk up by end of trading
The pot thickens: Cannabis stocks had a choppy Tuesday, as the market continues to fuel speculation with the potential for big winners -- and losers
Buds & Duds: Not a manic Monday as cannabis stocks calm down; Canopy Growth shares perk up on Manitoba news
Cannabis stocks had a quiet Monday overall when it comes to significant stock movements
Aleafia Health secures a spot on Horizons Marijuana Life Sciences ETF
The company recently teamed up with Cronos to study the effects of medical cannabis on insomnia
CryptoCann™ Report: Crypto leaders respond to NY Attorney General’s report; Maine restaurant sedates lobsters with pot before boiling
Crypto leaders hit back against a report from The NY Attorney General’s Office stating the exchanges are subject to manipulation
Cronos Group partners with Aleafia Health to work on medical cannabis study to treat insomnia
Physicians practicing within the Canabo Medical Clinic network, which is owned by Aleafia, will lead the study
Short-seller Andrew Left’s Citron Research says surge in cannabis company Tilray is 'beyond comprehension'
Left was previously bullish on Tilray but has since changed his tune
Beverage giant Coca-Cola interested in cannabis drinks, sending cannabis stocks higher
The Atlanta-based soft-drinks maker is in talks with Canadian marijuana producer Aurora Cannabis
StoneCastle Cannabis Growth Fund gives investors exposure to high-flying cannabis stocks
Fund manager Bruce Campbell tells cannabis investors to expect some ‘scary down days’ and consolidation before ‘the next phase up’
Tobacco player Alliance One International turns over a new (and greener) leaf as Pyxus International
Bob Byrne explains what the company’s transformation as Pyxus International means for cannabis investors
Cronos Group to launch second cannabis product in Canada called 'Spinach'
Canada is going to be the first G7 country to legalize cannabis in mid-October
Buds & Duds: Cannabis stocks continue to gain on Wednesday; Tilray shares climb despite negative press, Isodial shares pop on fiscal 1Q revenue
Cannabis stocks had a healthy day on Wednesday, with Tilray shares up significantly, despite negative news from short-seller Andrew Left of Citron Research. Isodiol International shares soared on news from first-quarter earnings results.
Buds & Duds: Cannabis stocks keep on rolling, Aphria shares rise as it exits the US market due to federal laws
Cannabis stocks bounced around on Thursday, with movers including Aphria Inc, which was up 15% after it released news it was exiting the US by completing the sale of its remaining holdings in Liberty Health Sciences Inc
Buds & Duds: Cannabis stocks continue their high bar; Valens GroWorks skyrockets
Cannabis stocks continued their rise on Wednesday, most notably, Valens GroWorks, which boosted 48% after it announced four new directors and was given a "buy" rating by analysts at Mackie Research
Buds & Duds: Cannabis stocks flying high; Canopy Growth surges to new heights, up 15%
Canopy Growth jumped to a new high on Tuesday, up 15.4% at C$68.83, making it the 45th biggest company on the Toronto Stock Exchange
Cronos Group stock jumps after partnering with Boston biotech Ginkgo Bioworks in a US$122mln deal to develop cultured cannabinoids
The biotech will genetically engineer cannabinoids so that Cronos can bring cannabinoid-based products to market with reliability and scalability
Tilray is the latest pot stock to come under attack from short-seller Andrew Left's Citron Research
Declaring Tilray too expensive, Left and his team are now taking a short bet against the cannabis stock
CryptoCann™ Report: Alibaba holds top spot for blockchain patents; Cronos inks deal for lab-grown cannabis
Cronos is partnering with Boston-based biotech Gingko Bioworks to develop lab-grown cannabis
Are marijuana stocks too high for an investor tempted to join the party, or do they have room to run?
Cronos stock recovers on Friday after saner voices intervened and defended the Canadian cannabis stock from a classic short-selling attack
Buds & duds: Cannabis stocks tumble after weeks of roller-coaster moves; Cronos Group down 28%
Cannabis stocks tumbled Thursday, most notably, Cronos Group, which dropped 28% after a US short-seller raised concerns the company may have withheld information
Cronos Group besieged by short-seller Andrew Left's Citron Research, shares fall and end sharply up Friday
The short selling firm calls Cronos the "most overhyped" of all the pot stocks and sets its price target at US$3.50
CryptoCann™ Report: Bithumb exchange welcomes new users again after hack; Cronos enters the Latin American market
The Canadian cannabis company entered into a joint venture agreement to begin cultivation in Colombia
Investments and investor services
CannaRoyalty’s focus beyond Canada is more than just California Dreamin’
Unlike most Canadian operators, CannaRoyalty has opted to direct the bulk of its attention in California
Cronos moves into Latin America with plans to cultivate cannabis in Colombia
The cannabis company entered a joint venture with an affiliate of Colombian agricultural provider Agroidea